

Ongoing trials with immunotherapy in SCLC

Trial name/NCT	Phase	Treatment	Allocation	Primary endpoint	Enrollment	Sponsor	PI
Limited stage							
Concurrent with chemoradiotherapy							
NCT03811002 (NRG-LU005)	II/III	Atezolizumab	Randomized	PFS/OS	506	National Cancer Institute (NCI), NRG Oncology	Kristin A Higgins
NCT03585998	II	Durvalumab	Single-arm	PFS	51	Samsung Medical Center	
NCT03509012 (CLOVER)	I	Durvalumab +/- tremelimumab + chemoradiotherapy	Non-randomized	safety	360	AstraZeneca	
NCT02402920	I	Pembrolizumab	Non-randomized	Safety	80	M.D. Anderson Cancer Center, National Cancer Institute (NCI)	James Welsh
After concurrent chemoradiotherapy							
NCT03703297 (ADRIATIC)	III	Durvalumab +/- tremelimumab	Randomized	PFS/OS	600	AstraZeneca	Haiyi Jiang
NCT02046733 (STIMULI)	II	Nivolumab + ipilimumab	Randomized	OS	264	European Thoracic Oncology Platform, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Center for Cancer Research of Lausanne, Frontier Science Foundation, Hellas, Bristol-Myers Squibb	Solange Peters, Dirk De Ruyscher
NCT03540420 (ACHILES)	II	Atezolizumab	Randomized	2 years OS	212	Multiple	Thorstein B Ro, MD, PhD
Extensive stage or recurrent							
First line							
NCT04028050 (MAURIS)	IIIB	Atezolizumab + chemotherapy	Single-arm	safety	150	Hoffmann-La Roche	
NCT04256421 (SKYSCRAPER-02)	III	Carboplatin, etoposide, atezolizumab +/- tiragolumab (anti-TIGIT)	Randomized	PFS, OS	400	Hoffmann-La Roche	Hoffmann-La Roche
NCT04012606	III	Toripalimab + chemotherapy	Randomized	PFS and OS	420	Shanghai Junshi Bioscience Co., Ltd.	
NCT04005716	III	Tislelizumab + chemotherapy	Randomized	PFS and OS	364	BeiGene	Ying Cheng, PhD
NCT04063163	III	HLX10 (anti-PD-1) + chemotherapy	Randomized	PFS	489	Shanghai Henlius Biotech	
NCT03382561	II	Nivolumab + chemotherapy	Randomized	PFS	150	National Cancer Institute (NCI)	Ticiana A Leal ECOG-ACRIN Cancer Research Group
NCT03568097 (PAVE)	II	Avelumab + chemotherapy	Single-arm	PFS	55	Hellenic Cooperative Oncology Group, Merck KGaA, Darmstadt, Germany	Helena Linardou, MD
NCT03041311	II	Carboplatin, etoposide, atezolizumab +/- trilaciclib (CDK4/6 inhibitor)	Randomized	effect on myelosuppression	105	G1 Therapeutics, Inc.	G1 Therapeutics, Inc.
NCT04221529 (SPACE)	II	Carboplatin, etoposide, atezolizumab in patients with ECOG PS 2	Single-arm	OS	70	AIO-Studien-gGmbH, Hoffmann-La Roche	Martin Reck, Prof. Dr.
First line maintenance							
NCT03516084	III	Niraparib as maintenance therapy following first-line chemotherapy	Randomized	PFS and OS	591	Zai Lab (Shanghai) Co., Ltd.	
NCT03410368	II	NK cell-based immunotherapy as maintenance therapy	Randomized	PFS	120	Jiuwei Cui	
NCT03983759	II	Chemotherapy plus R-CIK followed by sintilimab as maintenance therapy	Single-arm	OS	40	Henan Cancer Hospital	Jing Ding, Master
NCT04334941	II	Atezolizumab + talazoparib in patients SLFN11 Positive	Randomized	PFS	94	National Cancer Institute (NCI)	Nagla Abdel Karim
Second line and beyond							
NCT02963090	II	Pembrolizumab	Randomized	PFS	98	Alliance Foundation Trials, LLC, Merck Sharp & Dohme Corp.	Monica Bertagnoli
NCT03670056 (CA209-9YT)	II	Nivolumab + ipilimumab	Single-arm	Change in Teff/Treg	40	Yale University	Anne Chiang, MD, PhD
Ongoing trials with radiotherapy							
NCT04402788 (RAPTOR, NRG-LU007)	II/III	Atezolizumab +/- radiotherapy after chemotherapy and atezolizumab	Randomized	PFS and OS	324	National Cancer Institute (NCI)	
NCT02701400	II	Durvalumab + tremelimumab +/- radiotherapy	Randomized	PFS/ORR	18	Emory University, AstraZeneca	Taofeek Owonikoko
NCT02934503	II	Chemotherapy + pembrolizumab +/- radiotherapy	Single-arm	Change in PD-L1 expression	60	NYU Langone Health	Joshua Sabari, MD
NCT03262454	II	Sequential hypofractionated radiotherapy followed by atezolizumab	Single-arm	ORR	35	National Cancer Center, Korea, Roche Korea co.,Ltd.	Ji-Youn Han
NCT03262454	II	Hypofractionated radiation therapy followed by atezolizumab	Single-arm	ORR	35	National Cancer Center, Korea	Ji-Youn Han, Ph.D.
NCT03043599	I/II	Ipilimumab + nivolumab + thoracic radiotherapy after chemotherapy	Single-arm	PFS	21	H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb	Bradford A. Perez, M.D.
NCT02402920	I	Pembrolizumab + radiotherapy	Non-randomized	Safety	80	M.D. Anderson Cancer Center, National Cancer Institute (NCI)	James Welsh
NCT03923270	I	Thoracic radiotherapy + durvalumab +/- tremelimumab or olaparib	Non-randomized	safety, PFS	54	H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca	Alberto A Chiappori, MD
NCT03532880	I	Olaparib + low dose thoracic radiotherapy	Single-arm	safety	24	Memorial Sloan Kettering Cancer Center	Andreas Rimner, MD
NCT04170946	I	Talazoparib + low dose thoracic radiotherapy	Non-randomized	safety	24	University Health Network, Toronto, Pfizer	Benjamin Lok, MD
Ongoing trials with other agents							
NCT04192682	II	Anlotinib + sintilimab	Single-arm	PFS	40	Changzhou Cancer Hospital of Soochow University	Tong Zhou
NCT02554812 (JAVELIN medley)	II	Avelumab + utomilumab (antiCD137)	Randomized	ORR	600	Pfizer	Pfizer
NCT03728361	II	Nivolumab + temozolomide	Single-arm	ORR	53	Dwight Owen, National Cancer Institute (NCI)	Dwight Owen
NCT02628067	II	Pembrolizumab (biomarker analysis)	Single-arm	ORR	1395	Merck Sharp & Dohme Corp.	
NCT03958045	II	Rucaparib + nivolumab	Single-arm	PFS, OS	36	Aman Chauhan	Aman Chauhan
NCT03672773	II	Talazoparib + temozolomide	Single-arm	ORR	28	Jonsson Comprehensive Cancer Center, Translational Research in Oncology, National Cancer Institute (NCI)	Jonathan Goldman
NCT04010357	II	Abemaciclib (CDK4/6 inhibitor)	Single-arm	ORR	29	Case Comprehensive Cancer Center	Afshin Dowlati, MD
NCT04055792	II	Sintilimab + anlotinib	Randomized	PFS	52	Henan Cancer Hospital	
NCT03253068	II	Pembrolizumab + amurubicin	Single-arm	ORR	25	Wakayama Medical University, Merck Sharp & Dohme Corp.	
NCT03994744	II	Sintilimab + metformin	Single-arm	safety and ORR	68	Hunan Cancer Hospital	
NCT03406715	II	Nivolumab + ipilimumab + dendritic cell-based p53 vaccination	Single-arm	DCR	41	H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, MultiVlr, Inc.	Alberto Chiappori
NCT04079712	II	XL184 (Cabozantinib), Nivolumab, and Ipilimumab	Single-arm	ORR	30	National Cancer Institute (NCI)	Anteneh A Testfaye
NCT03126110	I/II	INCAGN01876 (anti-GITR) + nivolumab +/- ipilimumab in solid malignancies	Non-randomized	safety, ORR	285	Incyte Biosciences International Sàrl	John E. Janik
NCT03241173	I/II	INCAGN01949 (anti-OX40), + nivolumab +/- ipilimumab in solid malignancies	Non-randomized	Safety, ORR	52	Incyte Biosciences International Sàrl	John E. Janik
NCT02734004 (MEDIOLA)	I/II	Olaparib + durvalumab	Single-arm	safety, DCR, ORR	427	AstraZeneca	Susan Domcheck, MD
NCT03830918	I/II	Niraparib + temozolomide	Randomized	safety, PFS	64	Jonsson Comprehensive Cancer Center, Translational Research in Oncology, National Cancer Institute (NCI)	Jonathan Goldman
NCT02247349	I/II	Nivolumab + BMS-986012 (FucGM1 antibody)	Non-randomized	safety	172	Bristol-Myers Squibb	Bristol-Myers Squibb
NCT03227016	I/II	Veliparib + topotecan	Single-arm	safety	30	Central European Society for Anticancer Drug Research	Joachim von Pawel, MD
NCT02446704	I/II	Olaparib + temozolomide	Single-arm	Safety and ORR	106	Massachusetts General Hospital, AstraZeneca	Anna Farago, MD, PhD
NCT03575793	I/II	Nivolumab, ipilimumab + plinabulin	Randomized	Safety and PFS	55	Jyoti Malhotra	
NCT03554473	I/II	M7824 + topotecan or temozolomide	Non-randomized	ORR	67	National Cancer Institute (NCI)	Anish Thomas, M.D.
NCT04209595	I/II	PLX038 (PEGylated SN38) + rucaparib	Non-randomized	Safety and ORR	62	National Cancer Institute (NCI)	Anish Thomas, M.D.
NCT03126110	I/II	INCAGN01876 + nivolumab +/- ipilimumab	Non-randomized	Safety and ORR	285	Incyte Biosciences International Sàrl	John E. Janik
NCT02688673	I/II	Vaccination with dendritic cells plus cytokine-induced killer cells	Single-arm	ORR	30	Affiliated Hospital to Academy of Military Medical Sciences	
NCT03708328	I	PD-1/TIM-3 Bispecific Antibody (RO7121661)	Non-randomized	Safety, ORR, DCR, PFS	300	Hoffmann-La Roche	Hoffmann-La Roche
NCT04253145	I	Lurbinectedin + atezolizumab	Single-arm	Safety	25	Fundacion Oncosur	Santiago Ponce, MD
NCT03763149	I	CD47 monoclonal antibody Injection (IBI188)	Single-arm	Safety	42	Innovent Biologics (Suzhou) Co. Ltd.	
NCT03013218	I	Pembrolizumab + ALX148 (anti-CD47)	Non-randomized	Safety	184	ALX Oncology Inc.	
NCT03319940	I	AMG 757 (Bispecific T-cell engager targeting delta-like protein 3) +/- pembrolizumab	Randomized	Safety	162	Amgen	
NCT03392064	I	AMG 119 (Chimeric antigen receptor T-cell therapy targeting delta-like protein 3)	Non-randomized	Safety	6	Amgen	
NCT04173325	I	Nivolumab + irinotecan	Single-arm	Safety and ORR	10	Augusta University	Nagla A Karim, MD, PhD
NCT03228667	I	RO7121661 (PD-1/TIM-3 bispecific antibody)	Non-randomized	Safety, ORR, DCR, PFS	280	Hoffmann-La Roche	